Articles tagged with Drug Therapy
A new study by Massachusetts General Hospital researchers suggests that certain anti-cancer drugs may target a key player in Crohn's disease, a type of inflammatory bowel disease. The study found that mutations in a specific chromatin reader, SP140, are associated with an increased risk of immune diseases like Crohn's.
Researchers at Terasaki Institute create micro-organospheres for direct viral infection, immune cell penetration, and high-throughput therapeutic drug screening. The technology holds promise for personalized medicine, tumor therapy and rapid drug testing.
A Rutgers scientist has developed a highly sensitive DNA test that can detect Lyme disease in horses, a condition that can cause long-term complications. The test, called genomic hybrid capture assay, was tested on a sick horse and successfully identified the pathogen, allowing for early diagnosis and treatment.
A proof-of-concept study developed three machine learning models to predict posttreatment recurrence in early-stage hepatocellular carcinoma patients. The models achieved high accuracy using imaging data alone, while combining clinical data did not significantly improve performance.
Intravenous (IV) nutrition is being used by professional athletes as a regular routine, despite lack of scientific evidence supporting its effectiveness and potential risks. The 'food first' approach is crucial to avoid normalization of unproven treatments.
The study found a 31% decline in sleep medication use between 2013 and 2018, with the strongest decrease in FDA-approved medications. Behavioral treatments for insomnia are increasingly encouraged due to their effectiveness and reduced risk of adverse outcomes.
The study found an overall response rate of 57% and disease control rate of 83% in 23 patients with diverse cancer types. These results validate RET as a tissue-agnostic target with sensitivity to RET inhibition.
A comprehensive analysis of interstitial lung disease diagnosis and treatment in patients who received an antibody drug conjugate known as T-DXd found that close monitoring and proactive management can reduce the risk of ILD. The study results suggest that patient awareness and ongoing education can aid in early detection.
Researchers have discovered a functional link between STING signaling and immunometabolism, suggesting that PET imaging could measure the pharmacodynamic effects of STING-activating drugs. This approach may enable a whole-body analysis of immune activation in humans, guiding clinical development of anti-tumor therapy.
Researchers found that lidocaine injections reduced Psoriasis Area and Severity Index scores by 35-70% and maintained improvements for at least 24 weeks. The study suggests targeting sensory nerves as a potential therapeutic strategy for psoriasis treatment.
Researchers at Aston University have developed a new approach to tackle one of the underlying causes of asthma, not just its symptoms. The treatment, which targets the structural changes made by asthmatic airways, shows promising results in mice, reducing symptoms within two weeks and returning airways to near normal.
A study published in eLife identified three microRNAs that may impair healing in venous ulcers, a common type of chronic wound. The findings suggest that drugs targeting these microRNAs could help facilitate healing in patients, offering new approaches for treating this painful and slow-to-heal condition.
Researchers at Okayama University discovered EPA's molecular target, which blocks purinergic chemical transmission and reduces pain perception. The study suggests EPA can be used as a therapeutic strategy for managing chronic pain with fewer side effects.
Researchers found that administering tisagenlecleucel at the higher end of the approved dose range significantly improves overall and event-free survival in young patients. The study suggests that using higher doses of CAR-T therapy can achieve more effective and long-term responses without increasing toxicity risk.
Researchers developed a small molecule that effectively controls tumor growth by inhibiting PD-1/PD-L1 binding, overcoming accessibility and cost issues of existing antibody treatments. The new molecule has advantages in terms of affordability and oral administration, making immunotherapy more accessible to all cancer patients.
A clinical trial found that three smoking cessation treatments could also reduce alcohol consumption and found high rates of behavior change for both. Nicotine replacement therapy performed as well as prescription drugs in reducing alcohol intake.
The NCI-backed Molecular Targets Platform streamlines and catalyzes drug development by integrating pediatric cancer targets and pathways. This platform empowers researchers, pharmaceutical companies, and advocacy groups to accelerate the pace of drug development for pediatric cancer.
The August issues of American Psychiatric Association journals focus on neurodevelopmental and neurodegenerative illnesses. Featured research includes reports on mental health services for people with serious mental illness.
Researchers developed a non-invasive ocular imaging method to detect flavoprotein fluorescence in the eye, indicating mitochondrial oxidative stress. This technique may predict glaucoma progression earlier than current methods, with similar sensitivity to visual field changes.
Researchers at Nanyang Technological University in Singapore have developed a series of chemical-based compounds that could be potential drug candidates for treating pulmonary tuberculosis. The compounds were licensed by US-based Neuro-Horizon Pharma LLC for commercialization.
Leukemia cells exploit metabolic pathways to evade programmed cell death, but researchers identified a weak spot in acute lymphoblastic leukemia that can be targeted with experimental drugs. Inhibiting glutathione metabolism induces ferroptosis, leading to the death of malignant lymphocytes.
A team of researchers at Case Western Reserve University has discovered a cell signaling pathway responsible for the development of esophageal adenocarcinomas. The Ephrin B2 (EphB2) Tyrosine kinase pathway is activated during cancer growth and regulates the behavior of normal esophageal cells, making it an attractive therapeutic target.
The ISM Annual Meeting highlights new topics in oral, vaginal, skin, and gut microbiota, as well as their metabolites and potential implications in diseases like cancer, depression, and stroke. The meeting aims to explore the mechanism behind microbiota efficacy and its potential application in precision medicine.
A study of over 500 patients with multiple myeloma reveals a high prevalence of genetic alterations in oncogenic pathways, leading to treatment resistance. The research found a specific link between RASopathies and mutations in these pathways, offering new insights into the development of resistance mechanisms.
Researchers discovered that REM sleep disturbances are linked to increased risk of drug relapse, and that targeting MCH neurons may be a promising therapeutic approach. The study found that improving REM sleep reduced cocaine-seeking behavior in rats.
A team of scientists has discovered a key link between the protein αSyn and Parkinson's disease, finding that it interacts with immune responses in neurons. This interaction may play a critical role in the development of the disease, suggesting a potential new approach for treatments by targeting inflammatory pathways.
Hospitalized COVID-19 patients with high blood viscosity have a 60% higher death rate than those with low blood viscosity. The study suggests that checking for blood viscosity early on could help determine the best treatment course and improve outcomes.
A new treatment approach using antisense oligonucleotides (ASOs) may help reduce cystic fibrosis symptoms and improve quality of life for patients with a specific gene mutation. The ASO strategy tricks cells into making an imperfect but functional version of the CFTR protein, which is better than having none at all.
Researchers found that men who lose their Y chromosome as they age are more likely to experience deadly heart scarring and earlier death. The study suggests an existing drug may help counteract the effects of this loss, potentially leading to longer, healthier lives for affected men.
Researchers have created a new mouse model that mimics brain damage caused by severe RVFV infection, enabling the study of disease mechanisms and high-throughput testing of next-generation drugs. This breakthrough has significant implications for developing therapies and vaccines for this devastating virus.
Researchers used human heart muscle cells and machine learning to predict arrhythmias in patients, achieving over 90% accuracy. The study lays the foundation for safer and more effective medicines by generating patient risk profiles and drug toxicity testing.
A phase 3 clinical trial found that patients with relapsing-remitting multiple sclerosis treated with rituximab had a five-fold lower risk of relapse compared to those receiving standard dimethyl fumarate treatment. Rituximab also showed fewer new MS plaques on magnetic resonance imaging.
Researchers at University of Essex found no benefit from oxytocin administration on healthy men's ability to recognize emotions. Computer-based emotional training programs proved more effective in improving emotion recognition and mental health.
National data indicate that expanded access to methadone treatment during the COVID-19 pandemic did not lead to increased harms, but rather declined percentage of overdose deaths involving methadone. This evidence supports expanding take-home treatment for opioid use disorder.
Researchers at Edith Cowan University have found a genetic link between human leukocyte antigens and immunotherapy side effects in non-small cell lung cancer patients. The discovery enables doctors to tailor treatment to individual patients, reducing the risk of toxicities and improving overall outcomes.
Thousands of people with long covid are traveling abroad for expensive, unproven treatments like apheresis and anti-clotting therapy. Experts question the safety and effectiveness of these treatments, citing inadequate consent forms and lack of evidence.
A new AI technology called in silico FOCUS analyzes cell images to predict therapeutic effect of drugs for neurodegenerative disorders like Kennedy disease. The technology has 100% accuracy and can analyze several hundred thousand cells in just a few minutes.
Researchers at Aarhus University have developed an easy and inexpensive method for linking molecules to DNA sequences with desired functions. The method uses sulfonyl azides to introduce various functionalities, avoiding the need for expensive and unstable special phosphoramidites.
A recent clinical trial found that low-dose benzbromarone was more effective in reducing blood urate levels in patients with renal urate underexcretion. The study showed that more participants in the benzbromarone group achieved the target blood urate level of < 6 mg/dL compared to those receiving febuxostat.
Researchers have discovered a unique biochemical profile in severe asthmatic patients, which could lead to more effective treatments. The study found a decrease in carnitine metabolism in severe asthmatics, playing an important role in cellular energy generation and immune responses.
Researchers found a protein in eye fluid linked to disease progression in patients with wet age-related macular degeneration. Measuring its levels can accurately predict treatment needs, allowing for safe reduction or cessation of therapies.
Researchers have developed a new therapeutic agent from Brazilian lapacho tree bark that targets acute myeloid leukemia cells while minimizing toxic effects on healthy cells. The compound is attached to an antibody that binds specifically to cancer cells, delivering the drug directly to its target.
Researchers at Baylor College of Medicine have identified a potential more effective treatment for HER2 mutant metastatic breast cancer, poziotinib. The drug reduced tumor growth and multi-organ metastasis in laboratory tests and animal models.
Researchers at Stowers Institute for Medical Research have developed a precise model for the stinging organelle of the starlet sea anemone, revealing its complex architecture and firing mechanism. The findings could lead to beneficial applications in medicine, including microscopic therapeutic delivery devices.
A population-based study found that patients with estrogen receptor-positive breast cancer who experienced hot flashes while on adjuvant hormone therapy had worse outcomes and a higher risk of early treatment discontinuation. The study suggests that managing side effects may not be enough to prevent treatment discontinuation, highlight...
Researchers identified a three-gene signature in multiple myeloma tumors that predicts a positive response to selinexor-based therapy. The discovery could improve patient selection for targeted agents and expand the use of the drug into patients who haven't failed other therapies.
A novel targeted radionuclide alpha therapy, AC-NM600, has been shown to achieve significantly better outcomes than its corresponding beta therapy in treating metastatic castration-resistant prostate cancer. The study demonstrated slowed tumor growth and improved overall survival.
A new study by Vertice Pharma confirms that drinking coffee does not affect the absorption of a liquid formulation of levothyroxine. The research suggests that patients can take their medication with coffee without worrying about reduced absorption. This finding could lead to more flexibility in dosing and improved patient outcomes.
Researchers found thalidomide to be an effective treatment for severe arteriovenous malformations (AVMs), reducing symptoms and improving quality of life in patients. The study showed a striking reduction in symptoms, with some patients experiencing complete cure after treatment.
Researchers at the University of Cincinnati are studying how lipids help fortify lung cancer cells and if targeting them can lead to better outcomes. The team discovered that lipids play a crucial role in cancer cell growth, membrane fortification, and energy production.
A novel BRAF inhibitor, C1a, has been developed to cross the blood-brain barrier and treat melanoma brain metastasis. The study found that C1a triggered robust responses in patient-derived models and outperformed approved BRAF inhibitors, achieving significant increases in survival rates.
A new study found that circulating tumor DNA can identify stage II colon cancer patients who benefit from chemotherapy, sparing others the need for treatment. The study showed reduced use of chemotherapy without compromising survival rates.
Researchers have identified new biomarkers to detect non-small cell lung cancer in its early stages through a blood test, offering improved survival chances. The approach can also identify potential drug resistance, allowing clinicians to choose alternative treatment options.
A new cell therapy has been developed to target and eliminate leukemia stem cells that cause disease relapse. The treatment uses genetically engineered T cells with a chimeric antigen receptor that recognizes specific markers on these cancer cells.
Researchers at the University of Chicago's Pritzker School of Molecular Engineering have developed a version of interleukin-12 that is activated only when it reaches a tumor, reducing side effects. The new 'masked' molecule has shown promising results in eliminating cancer cells and outperforming existing immune therapies.
Researchers found that inhibiting caspase 11 reduced inflammation, tissue injury and blood clots in lung tissue of infected mice. This suggests potential therapeutic targets for treating severe COVID-19 symptoms.
A retrospective analysis of 7,000 patients found pulse oximeter devices overestimated blood oxygen levels in non-White patients, delaying treatment eligibility recognition. The study suggests that biases in pulse oximeter accuracy disproportionately affect minority communities.
Researchers found that severe asthma patients produce growth factors that block corticosteroids from working, leading to frequent breathing problems. This discovery may lead to new treatments targeting these growth factors to improve outcomes for patients with severe asthma.
Research found that hypomethylating agents (HMAs) activated the oncofetal protein SALL4 in up to 40% of patients with MDS, resulting in poor patient survival. This activation is linked to demethylation and upregulation of oncogenes, suggesting a need for additional combination therapy.
Researchers at Keck School of Medicine of USC are testing the efficacy of 3K3A-APC as a cerebroprotectant to reduce brain bleeds in acute ischemic stroke patients. The experimental drug has shown promising results in Phase 2 clinical trials, reducing incidence of brain hemorrhage by nearly 20%.